

AMENDMENTS TO THE DRAWINGS

The attached sheet of drawings include changes to Figure 7 correcting typographical errors. The accompanying amended Figure 7 (as amended in parent application USSN 09/565,616) is amended to change the nucleotide position listed as "3210" to "2382," and to reverse the positions of "5213" and "5303" and replaces the original sheet.

REMARKS

Claims 1-15 are cancelled. Cancellation of these claims is without prejudice, without intent to abandon any originally-claimed subject matter, and without intent to acquiesce in any rejection of record. Applicants expressly reserve the right to file one or more continuing applications containing these cancelled claims.

Claims 16-27 are currently pending with entry of this Amendment. With respect to claims 16-27, support for the methods for stable expression of a transgene in a eukaryotic host cell can be found throughout the specification. For example, see the specification at page 9, lines 22-24; page 12, lines 24-33; page 13, lines 1-30; page 14, line 1 through page 15, line 11; page 16, lines 17-22; and the originally-filed claims. Applicants submit that no new matter has been added to the application by way of the above Amendment. Accordingly, entry of the Amendment is respectfully requested.


Applicants have also amended the specification to correct various typographical errors. Support for these corrections can be found at, for example, page 12, lines 1-8, Figure 1, and in the attached copy of the ATCC "Receipt in the case of an original deposit issued pursuant to Rule 7.3 and viability statement issued pursuant to Rule 10.2". Applicants note that the specified cell line has been deposited under the Budapest Treaty under the company's previous name "Biosource Technologies, Inc."; furthermore, this cell line will irrevocably and without restriction be released to the public upon issuance of the pending claims in the allowed parent application (USSN 09/565,616). No new matter has been added to the application by way of the above amendment.

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 510-337-7871.

QUINE INTELLECTUAL
PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Respectfully submitted,

A handwritten signature in cursive script that reads "Angela P. Home, Ph.D.".

Angela P. Home, Ph.D.
Reg. No. 41,079